Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.

doi:10.1200/JCO.21.00217

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2021

Kang Yoon-Koo, George Suzanne, Jones Robin L, Rutkowski Piotr, Shen Lin, Mir Olivier, Patel Shreyaskumar, Zhou Yongjian, von Mehren Margaret, Hohenberger Peter, Villalobos Victor, Brahmi Mehdi, Tap William D, Trent Jonathan, Pantaleo Maria A, Schöffski Patrick, He Kevin, Hew Paggy, Newberry Kate, Roche Maria, Heinrich Michael C, Bauer Sebastian

Abstract excerpt

PURPOSE: Primary or secondary mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors (GISTs). Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant kinases. In the phase I NAVIGATOR study (NCT02508532), avapritinib showed clinical activity against PDGFRA D842V-mutant and later-line KIT-mutant GIST. VOYAGER...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Phenylurea Compounds

Share to Progression-Free Survival

Share to Pyrazoles

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 34343033
DOI: 10.1200/JCO.21.00217
PMCID: PMC8478403

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.PMID 34343033Read ↗

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.Semantic proximity Read ↗

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.Semantic proximity Read ↗

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world dataSemantic proximity Read ↗

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.Semantic proximity Read ↗

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.Semantic proximity Read ↗

Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.Semantic proximity Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Avapritinib for metastatic or unresectable gastrointestinal stromal tumors.Semantic proximity Read ↗

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.Semantic proximity Read ↗

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.